SymphoRNA establishes presence at SBC to advance next generation RNA therapeutics

The company has moved into the Seed Works and will continue its development of RNA therapeutics enabled by a polysaccharide based delivery platform.

SymphoRNA has joined Stevenage Bioscience Catalyst this November, marking an exciting step in the company’s development. The team has moved into Seedworks, SBC’s collaborative office environment for early stage companies, and is developing next generation RNA therapeutics using a polysaccharide based delivery platform that can deliver multiple RNAs in combination rather than focusing on a single pathway. This approach has the potential to treat diseases driven by several biological mechanisms simultaneously, expanding the reach of RNA therapeutics into areas where single-target strategies have struggled. The company is led by Ruth Faram, CEO and Founder, who brings significant experience across UK life sciences, including senior scientific and commercial roles. She is joined by the SymphoRNA team, who are now beginning their first month on campus.

Founder and CSO Ruth Faram says:

“We are delighted to establish our presence at SBC and launch into Seedworks co shared office space. This is a fantastic opportunity to connect with a vibrant community of early stage health innovation companies. Having recently taken part in the Big Pharma Reverse Pitch, we saw first hand the value of SBC’s network, investors and business development ecosystem. Having a base so close to London and Cambridge where much of our team comes from is a big advantage.”

SymphoRNA becomes part of SBC’s diverse and rapidly evolving life science community. The company will gain access to networking opportunities, peer learning, business support and shared infrastructure designed to help early stage ventures scale.

If you would like to know more about SymphoRNA or space availability at SBC, please reach out to Marco Delise.